Home > Insider Trading > Filing (0000899243-20-025618)

Filing Details

Accession Number:: 0000899243-20-025618
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2020-09-17 21:22:57
Reporting Period:: 2020-09-04

Accepted Time:: 2020-09-17 21:22:57
Original Submission Date:: 2020-09-15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1394319	Tracon Pharmaceuticals Inc.	TCON	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1778253	Ikarian Capital, Llc	100 Crescent Court, Suite 1620 Dallas TX 75201	No	No	Yes	Yes
1824857	Neil Shahrestani	100 Crescent Court, Suite 1620 Dallas TX 75201	No	No	Yes	Yes
1824870	Ikarian Healthcare Master Fund, L.p.	100 Crescent Court, Suite 1620 Dallas TX 75201	No	No	Yes	Yes
1825179	Trust Living Westcott Chart	100 Crescent Court, Suite 1620 Dallas TX 75201	No	No	Yes	Yes
1825313	Ikarian Healthcare Fund Gp, L.p.	100 Crescent Court, Suite 1620 Dallas TX 75201	No	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2020-09-04	151,611	$2.87	1,991,689	No	4	P	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2020-09-08	13,244	$2.90	2,004,933	No	4	P	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2020-09-09	79,415	$3.49	2,084,348	No	4	P	Indirect	See Footnotes
Common Stock, Par Value $0.001 Per Share	Acquisiton	2020-09-11	78,201	$3.93	2,162,549	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

This price represents the approximate weighted average price per Share of purchases that were executed at prices ranging from $2.7981 to $2.9986 per Share. The Reporting Persons undertake to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the price per Share and the number of Shares purchased at each price.
This statement is jointly filed by and on behalf of each of the Reporting Persons. Ikarian Capital is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian Capital is also the general partner of, and may be deemed to indirectly beneficially own, securities beneficially owned by Ikarian GP.
Ikarian Capital is a sub-advisor for certain separate managed accounts (collectively, the "Managed Accounts") and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Ikarian Capital is ultimately owned and controlled by the Trust, and indirectly by Mr. Shahrestani. Accordingly, each of Mr. Westcott, as sole trustee of the Trust, and Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by, Ikarian Capital. The Fund and the Managed Accounts are the record and direct beneficial owners of the securities covered by this statement. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts.
The Reporting Persons state that neither the filing of this statement nor anything herein shall be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any securities covered by this statement. The Reporting Persons disclaim beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Persons in such securities.
The Reporting Persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for purposes of Section 13(d) or 13(g) of the Exchange Act. The Reporting Persons declare that neither the filing of this statement nor anything herein shall be construed as an admission that such persons are, for the purposes of Section 13(d) or 13(g) of the Exchange Act or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer.